Open Access iconOpen Access

ARTICLE

crossmark

Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma

WEI BAO1,#, QIANGUANG HAN2,#, XIAO GUAN3, ZIJIE WANG2, MIN GU1,2,*

1 Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China
2 Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3 Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

* Corresponding Author: MIN GU. Email: email
# These authors are co-first authors

(This article belongs to the Special Issue: Transcriptome Analysis in Tumor Microenvironment and Tumor Heterogeneity)

Oncology Research 2023, 31(2), 181-192. https://doi.org/10.32604/or.2023.028051

Abstract

Background: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. Methods: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk profiles of patients with ccRCC. Patients in each cohort were separated into high- and low-risk groups based on their risk scores. The clinical importance of the signature was assessed through survival, immune microenvironment, drug sensitivity, and nomogram analyses using R software. Results: SLC25A23, SLC25A42, SLC5A1, SLC3A1, SLC25A37, SLC5A6, SLCO5A1, and SCP2 comprised the signatures of the eight SLC-related genes. Patients with ccRCC were separated into high- and low-risk groups based on the risk value in the training and validation cohorts; the high-risk group had a significantly worse prognosis (p < 0.001). The risk score was an independent predictive indicator of ccRCC in the two cohorts according to univariate and multivariate Cox regression (p < 0.05). Analysis of the immune microenvironment showed that immune cell infiltration and immune checkpoint gene expression differed between the two groups (p < 0.05). Drug sensitivity analysis showed that compared to the low-risk group, the high-risk group was more sensitive to sunitinib, nilotinib, JNK-inhibitor-VIII, dasatinib, bosutinib, and bortezomib (p < 0.001). Survival analysis and receiver operating characteristic curves were validated using the E-MTAB-1980 cohort. Conclusions: SLC-related genes have predictive relevance in ccRCC and play roles in the immunological milieu. Our results provide insight into metabolic reprogramming in ccRCC and identify promising treatment targets for ccRCC.

Keywords


Supplementary Material

Supplementary Material File

Cite This Article

APA Style
BAO, W., HAN, Q., GUAN, X., WANG, Z., GU, M. (2023). Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma. Oncology Research, 31(2), 181-192. https://doi.org/10.32604/or.2023.028051
Vancouver Style
BAO W, HAN Q, GUAN X, WANG Z, GU M. Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma. Oncol Res. 2023;31(2):181-192 https://doi.org/10.32604/or.2023.028051
IEEE Style
W. BAO, Q. HAN, X. GUAN, Z. WANG, and M. GU "Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma," Oncol. Res., vol. 31, no. 2, pp. 181-192. 2023. https://doi.org/10.32604/or.2023.028051



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1431

    View

  • 944

    Download

  • 1

    Like

Share Link